title: Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials.
abstract: Objective. To conduct a comprehensive PRISMA-compliant systematic review and meta-analysis to evaluate the efficacy and safety of Chinese medicines (CMs) as an adjuvant therapy for unresectable HCC during transarterial chemoembolization (TACE). Methods. Main databases were searched up to October 2012 for randomized controlled trials (RCTs) evaluating the effects of CMs plus TACE on unresectable HCC compared with TACE alone. References of relevant reviews and eligible studies were also assessed. Risk ratios with 95% confidence intervals and mean difference were calculated. Heterogeneity and publication bias were examined. Results. Sixty-seven trials (N = 5,211) were included in the meta-analysis. Sensitivity analysis and random-effects model were performed for assessing significant heterogeneity. CMs plus TACE showed beneficial effects on tumor response, survival at 6, 12, 18, 24, and 36 months, quality of life, and TACE toxicity reduction compared with TACE alone. Conclusion. The results show that the use of CMs may increase the efficacy and reduce the toxicity of TACE in treating patients with unresectable HCC. These findings suggest that CMs could be considered as an adjuvant therapy for unresectable HCC patients during TACE. Larger-scale RCTs using standard methods and long-term follow-up are warranted to confirm these findings.
authors: School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.
authors: Fan
authors: F
authors: Cheung
authors: Xuanbin
authors: X
authors: Wang
authors: Ning
authors: N
authors: Wang
authors: Man-Fung
authors: MF
authors: Yuen
authors: Tat-Chi
authors: TC
authors: Ziea
authors: Yao
authors: Y
authors: Tong
authors: Vivian Taam
authors: VT
authors: Wong
authors: Yibin
authors: Y
authors: Feng
references: Altern Med Rev. 2004 Sep;9(3):259-74
references: 15387718
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Mol Carcinog. 2009 Jun;48(6):498-507
references: 18973184
references: Cancer. 2002 Mar 15;94(6):1747-52
references: 11920537
references: J Ethnopharmacol. 2012 Sep 28;143(2):680-5
references: 22867634
references: J Ethnopharmacol. 2011 Jun 14;136(1):279-82
references: 21524699
references: Am J Gastroenterol. 2003 May;98(5):1181-5
references: 12809846
references: J Ethnopharmacol. 2010 Sep 15;131(2):396-403
references: 20633624
references: Mol Med Rep. 2012 Mar;5(3):637-44
references: 22159471
references: Int J Biol Macromol. 2012 Dec;51(5):788-93
references: 22829051
references: J Korean Med Sci. 2001 Dec;16 Suppl:S28-37
references: 11748374
references: World J Gastroenterol. 2007 Jan 28;13(4):557-63
references: 17278221
references: J Ethnopharmacol. 2005 Feb 10;97(1):21-9
references: 15652270
references: Cancer. 1981 Jan 1;47(1):207-14
references: 7459811
references: Biol Pharm Bull. 2008 May;31(5):826-30
references: 18451501
references: Cancer Lett. 2007 Jul 8;252(1):43-54
references: 17223259
references: BMJ. 2010 Mar 23;340:c332
references: 20332509
references: Planta Med. 2011 May;77(7):681-91
references: 21347995
references: Ann Oncol. 2002;13 Suppl 4:127-9
references: 12401678
references: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009 Mar;29(3):225-7
references: 19548439
references: Immunopharmacology. 1995 Jun;30(1):79-87
references: 7591716
references: Evid Based Complement Alternat Med. 2012;2012:371286
references: 22792123
references: Oncology. 2011;81 Suppl 1:123-33
references: 22212946
references: Int J Oncol. 2011 Sep;39(3):735-45
references: 21687936
references: Cancer Biol Ther. 2007 Dec;6(12):2005-11
references: 18087221
references: J Altern Complement Med. 2008 Oct;14(8):1027-42
references: 18990050
references: Int J Biol Macromol. 2012 May 1;50(4):891-4
references: 22285989
references: Prev Chronic Dis. 2008 Jul;5(3):A74
references: 18558024
references: BMJ. 2010 Mar 23;340:c869
references: 20332511
references: J Clin Oncol. 2006 Jan 20;24(3):419-30
references: 16421421
references: Expert Opin Investig Drugs. 2009 May;18(5):617-35
references: 19388879
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Int J Mol Med. 2009 Feb;23(2):189-96
references: 19148542
references: J Ethnopharmacol. 2010 Apr 21;128(3):654-61
references: 20193751
references: Chin Med. 2010 Aug 20;5:30
references: 20727161
references: World J Gastroenterol. 2011 Apr 7;17(13):1685-9
references: 21483627
references: Thromb Res. 2012 Sep;130(3):409-14
references: 22560337
references: Br J Pharmacol. 2011 Sep;164(2b):731-42
references: 21418191
references: J Clin Epidemiol. 2001 Oct;54(10):1046-55
references: 11576817
references: J Ethnopharmacol. 2012 Sep 28;143(2):406-11
references: 22820242
references: Integr Cancer Ther. 2005 Sep;4(3):219-29
references: 16113029
references: BMJ. 2009 Jul 21;339:b2535
references: 19622551
references: Arch Pharm Res. 2003 Oct;26(10):832-9
references: 14609132
references: J Cell Physiol. 2012 Oct;227(10):3363-72
references: 22213398
references: Biol Pharm Bull. 2006 Jun;29(6):1082-6
references: 16754997
references: Mol Carcinog. 2011 Aug;50(8):580-91
references: 21319226
references: J Nat Prod. 2011 Feb 25;74(2):137-44
references: 21250700
references: Integr Cancer Ther. 2011 Jun;10(2):168-77
references: 21190953
references: Molecules. 2007 Sep 05;12(9):2140-50
references: 17962732
references: Ann Surg. 2011 Mar;253(3):453-69
references: 21263310
references: Hepatobiliary Pancreat Dis Int. 2011 Jun;10(3):303-7
references: 21669575